Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808899 · ClinicalTrials.gov registry record · Phase 2
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00808899 is a Phase 2 study that was terminated before completion, run by St. Jude Children's Research Hospital. The registered enrollment target is 4 participants.
The verdict
NCT00808899, a Phase 2 study, was terminated before completion, sponsored by St. Jude Children's Research Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses of induction chemotherapy and then intensification with autologous hematopoietic stem cell transplantation. The first five courses of induction chemotherapy will also evaluate the feasibility of combining weekly temsirolimus with these standard chemotherapy combinations. This will be followed by 16 months of oral maintenance therapy with eight months of 13-cis-retinoic acid and then eight months of oral topotecan.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Irinotecan
- DRUG Temsirolimus
- PROCEDURE Surgical Resection of Primary Tumor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808899
The ClinicalTrials.gov registry entry for NCT00808899 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00808899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00808899 about?
NCT00808899 is a clinical study titled "Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma". A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses of induction chemotherapy and then intensification with autologous hema...
What is the current status of trial NCT00808899?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00808899?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Irinotecan (DRUG), Temsirolimus (DRUG), Surgical Resection of Primary Tumor (PROCEDURE).
Who is sponsoring clinical trial NCT00808899?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.